We downgrade BYRCS topline/EBITDA/APAT estimates by 1%/9%/9% for FY21, 1%/4%/5% for FY22 and 1%/7%/8% for FY23. We roll over to FY23 estimates and maintain Accumulate rating with revised target price of Rs 6022 (Previous TP 6090) based on 35x FY23 EPS of Rs 172. Bayer reported disappointing results. While topline was in-line with our estimates @ Rs 9.2 bn with 8% growth (PLe Rs 9.3 bn), gross margin contracted by sharp 542 bps due to lower sales of high margin corn seeds and product repositioning...